Heparin-induced thrombocytopenia causes: Difference between revisions
Rim Halaby (talk | contribs) m (Changed protection level for "Heparin-induced thrombocytopenia causes" ([Edit=Allow only autoconfirmed users] (expires 14:29, 7 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 14:29, 7 January 2014 (UTC)))) |
Tarek Nafee (talk | contribs) (→Causes) |
||
(5 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Heparin-induced thrombocytopenia}} | {{Heparin-induced thrombocytopenia}} | ||
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu] | {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu] {{shyam}} | ||
==Overview== | ==Overview== | ||
[[Heparin-induced thrombocytopenia]] is | [[Heparin-induced thrombocytopenia]] is caused by a variety of factors. It is typically caused by unfractionated heparin (moreso than low-molecular weight heparin). Females are more likely to develop HIT. Patients undergoing cardiac surgery are more likely to develop HIT. | ||
==Causes== | ==Causes== | ||
* Duration of heparin treatment | * HIT is always caused by exogenous heparin or heparinoid exposure. | ||
* The type of heparin involved | * Duration of [[heparin]] treatment: long duration, up to 2 weeks is associated with the greatest risk.<ref name="pmid23714311">{{cite journal| author=Lee GM, Arepally GM| title=Diagnosis and management of heparin-induced thrombocytopenia. | journal=Hematol Oncol Clin North Am | year= 2013 | volume= 27 | issue= 3 | pages= 541-63 | pmid=23714311 | doi=10.1016/j.hoc.2013.02.001 | pmc=3668315 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23714311 }} </ref> | ||
* The type of [[heparin]] involved: unfractionated heparin ([[UFH]]) puts patients at greater risk of HIT than [[low molecular weight heparin]] LMWH.<ref name="pmid23714311">{{cite journal| author=Lee GM, Arepally GM| title=Diagnosis and management of heparin-induced thrombocytopenia. | journal=Hematol Oncol Clin North Am | year= 2013 | volume= 27 | issue= 3 | pages= 541-63 | pmid=23714311 | doi=10.1016/j.hoc.2013.02.001 | pmc=3668315 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23714311 }} </ref> | |||
==Reference== | ==Reference== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
{{WS}} | |||
{{WH}} | {{WH}} | ||
Latest revision as of 15:23, 18 August 2017
Heparin-induced thrombocytopenia |
Differentiating Heparin-induced thrombocytopenia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Heparin-induced thrombocytopenia causes On the Web |
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia causes |
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
Risk calculators and risk factors for Heparin-induced thrombocytopenia causes |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Aric C. Hall, M.D., [3] Shyam Patel [4]
Overview
Heparin-induced thrombocytopenia is caused by a variety of factors. It is typically caused by unfractionated heparin (moreso than low-molecular weight heparin). Females are more likely to develop HIT. Patients undergoing cardiac surgery are more likely to develop HIT.
Causes
- HIT is always caused by exogenous heparin or heparinoid exposure.
- Duration of heparin treatment: long duration, up to 2 weeks is associated with the greatest risk.[1]
- The type of heparin involved: unfractionated heparin (UFH) puts patients at greater risk of HIT than low molecular weight heparin LMWH.[1]
Reference
- ↑ 1.0 1.1 Lee GM, Arepally GM (2013). "Diagnosis and management of heparin-induced thrombocytopenia". Hematol Oncol Clin North Am. 27 (3): 541–63. doi:10.1016/j.hoc.2013.02.001. PMC 3668315. PMID 23714311.